The Firefly Dx is a hand-held device that utilizes polymerase chain reactions (PCR) in order to detect a variety of different biological agents. GenArraytion is involved in the development of biological testing assays for biological threats and other pathogens that are currently clinically relevant. Its MultiFLEX Bioassays feature up to 20 DNA and RNA targets within a single unit.
"We are very interested in the work PositiveID is doing with its Firefly Dx, which could significantly advance the capabilities of the real-time PCR market, and we are pleased to partner with them to test our assays on this exciting and essential point-of-need technology platform," R. Paul Schaudies, CEO of GenArraytion, said.
The Firefly system has been successful in clinical testing. The device is an alternative to cumbersome laboratory tests that can be difficult or impossible to complete in remote areas. With the MultiFLEX assays from GenArraytion, both companies hope to further advance development of both the device and the assays.
"GenArraytion's competencies and real-time PCR assays are first rate, which is evidenced by their world-class customer base, and we believe our cooperative experience will provide us an opportunity to further advance the development and testing of Firefly Dx," Lyle Probst, president of PositiveID, said.